Trial reportScientific reports2017
Investigation of novel metabolites potentially involved in the pathogenesis of coronary heart disease using a UHPLC-QTOF/MS-based metabolomics approach.
Trial report in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 55 citations in OpenAlex.
- Serum Vitamin A Is Associated with Variations in the Relationship between Plasma B6 Vitamers and Cardiovascular Disease Risk.The Journal of nutrition · 2026Trial
- Causal effects between blood metabolites and myocardial infarction: A 2-sample Mendelian randomization study.Medicine · 2026Article
- Microneedle-mediated delivery of Coptis chinensis-derived nanovesicles orchestrating antibacterial and macrophage reprogramming for comprehensive wound healing.Journal of nanobiotechnology · 2026Article
- Dietary patterns influencing the human colonic microbiota from infancy to centenarian age: a narrative review.Frontiers in nutrition · 2025Review
- Lipidomics-Based Identification of Plasma Lipid Biomarkers in Tuberculosis-Coronary Artery Disease Comorbidity.Infection and drug resistance · 2025Article
- The gut-heart axis: unveiling the roles of gut microbiota in cardiovascular diseases.Frontiers in cardiovascular medicine · 2025Review
- The Therapeutic Potential of the Specific Intestinal Microbiome (SIM) Diet on Metabolic Diseases.Biology · 2024Review
- MASH: MEDIATION ANALYSIS OF SURVIVAL OUTCOME AND HIGH-DIMENSIONAL OMICS MEDIATORS WITH APPLICATION TO COMPLEX DISEASES.The annals of applied statistics · 2024Article
- MASH: MEDIATION ANALYSIS OF SURVIVAL OUTCOME AND HIGH-DIMENSIONAL OMICS MEDIATORS WITH APPLICATION TO COMPLEX DISEASES.bioRxiv : the preprint server for biology · 2024Article
- Forensic identification of sudden cardiac death: a new approach combining metabolomics and machine learning.Analytical and bioanalytical chemistry · 2023Article
- Emerging Roles of Gut Microbial Modulation of Bile Acid Composition in the Etiology of Cardiovascular Diseases.Nutrients · 2023Review
- Gut Microbiota and Sex Hormones: Crosstalking Players in Cardiometabolic and Cardiovascular Disease.International journal of molecular sciences · 2022Review
- A HILIC-MS/MS method development and validation for the quantitation of 13 acylcarnitines in human serum.Analytical and bioanalytical chemistry · 2022Article
- A Review on the Health Effects of Pesticides Based on Host Gut Microbiome and Metabolomics.Frontiers in molecular biosciences · 2021Review
- Panomics: New Databases for Advancing Cardiology.Frontiers in cardiovascular medicine · 2021Review
- Untargeted GC-MS investigation of serum metabolomics of coronary artery disease patients.Saudi journal of biological sciences · 2020Article
- Article
- Urinary metabolites and risk of coronary heart disease: A prospective investigation among urban Chinese adults.Nutrition, metabolism, and cardiovascular diseases : NMCD · 2020Article
- Association of Circulating Metabolites With Risk of Coronary Heart Disease in a European Population: Results From the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) Consortium.JAMA cardiology · 2019Article
- 4-Pyridoxic Acid/Pyridoxine Ratio in Patients with Type 2 Diabetes is Related to Global Cardiovascular Risk Scores.Diagnostics (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary heart disease (CHD) is associated with complex metabolic disorders, but its molecular aetiology remains unclear. Using a novel nontargeted metabolomics approach, we explored the global metabolic perturbation profile for CHD. Blood samples from 150 patients with severe obstructive CHD and 150 angiographically normal controls were collected. Metabolic fingerprinting was performed by ultra-high performance liquid chromatography coupled to quadruple time-of-flight mass spectrometry (UHPLC-QTOF/MS) technique. After adjusting for CHD traditional risk factors and metabolic batch, a comprehensive list of 105 metabolites was found to be significantly altered in CHD patients. Among the metabolites identified, six metabolites were discovered to have the strongest correlation with CHD after adjusting for multiple testing: palmitic acid (β = 0.205; p < 0.0001), linoleic acid (β = 0.133; p < 0.0001), 4-pyridoxic acid (β = 0.142; p < 0.0001), phosphatidylglycerol (20:3/2:0) (β = 0.287; p < 0.0001), carnitine (14:1) (β = 0.332; p < 0.0001) and lithocholic acid (β = 0.224; p < 0.0001); of these, 4-pyridoxic acid, lithocholic acid and phosphatidylglycerol (20:3/2:0) were, to the best of our knowledge, first reported in this study. A logistic regression model further quantified their positive independent correlations with CHD. In conclusion, this study surveyed a broad panel of nontargeted metabolites in Chinese CHD populations and identified novel metabolites that are potentially involved in CHD pathogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.